About
Convergent Genomics develops UroAmp, a non-invasive genomic urine test that uses next-generation sequencing of urine DNA to detect, monitor, and predict the risk of bladder cancer with high accuracy.
Explore Convergent Genomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.